X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10552) 10552
Newsletter (306) 306
Newspaper Article (52) 52
Book Chapter (29) 29
Magazine Article (17) 17
Dissertation (9) 9
Conference Proceeding (2) 2
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7496) 7496
tacrolimus (6485) 6485
male (5431) 5431
female (4752) 4752
transplantation (4029) 4029
tacrolimus - administration & dosage (3691) 3691
adult (3478) 3478
middle aged (3289) 3289
immunosuppressive agents - administration & dosage (3272) 3272
immunosuppressive agents - therapeutic use (2782) 2782
tacrolimus - therapeutic use (2710) 2710
surgery (2378) 2378
animals (2226) 2226
cyclosporine (1927) 1927
treatment outcome (1881) 1881
immunology (1818) 1818
pharmacology & pharmacy (1629) 1629
immunosuppressive agents - adverse effects (1571) 1571
aged (1512) 1512
kidney transplantation (1502) 1502
tacrolimus - adverse effects (1447) 1447
immunosuppression (1378) 1378
adolescent (1339) 1339
dermatology (1200) 1200
child (1171) 1171
calcineurin inhibitors (1131) 1131
drug therapy, combination (1108) 1108
graft rejection - prevention & control (1099) 1099
immunosuppressive agents - pharmacokinetics (1099) 1099
fk506 (1094) 1094
tacrolimus - pharmacology (1083) 1083
rats (1075) 1075
kidneys (1062) 1062
pharmacokinetics (1051) 1051
tacrolimus - pharmacokinetics (1039) 1039
recipients (1036) 1036
retrospective studies (960) 960
time factors (954) 954
analysis (937) 937
administration, topical (932) 932
liver transplantation (859) 859
dose-response relationship, drug (858) 858
immunosuppressive agents - pharmacology (841) 841
mycophenolic acid - analogs & derivatives (834) 834
liver (810) 810
therapy (807) 807
young adult (804) 804
immunosuppressive agents (801) 801
follow-up studies (794) 794
research (771) 771
drug administration schedule (755) 755
health aspects (750) 750
risk factors (743) 743
cyclosporine-a (725) 725
organ transplant recipients (707) 707
cyclosporine - administration & dosage (700) 700
prospective studies (690) 690
transplants & implants (688) 688
child, preschool (685) 685
immunotherapy (674) 674
cyclosporine - therapeutic use (667) 667
children (660) 660
tacrolimus - blood (658) 658
dosage and administration (651) 651
efficacy (650) 650
mice (641) 641
mycophenolate-mofetil (620) 620
fk-506 (613) 613
immunosuppressive agents - blood (609) 609
pediatrics (608) 608
mycophenolic acid - administration & dosage (593) 593
drug therapy (592) 592
administration, oral (591) 591
corticosteroids (589) 589
medicine & public health (588) 588
care and treatment (585) 585
tacrolimus - analogs & derivatives (579) 579
rejection (559) 559
mycophenolate mofetil (541) 541
graft rejection (531) 531
sirolimus (529) 529
dermatitis, atopic - drug therapy (519) 519
mycophenolic acid - therapeutic use (509) 509
kidney-transplantation (500) 500
renal-transplantation (497) 497
graft survival (491) 491
kidney transplantation - immunology (488) 488
safety (483) 483
atopic dermatitis (477) 477
transplantation, homologous (475) 475
graft survival - drug effects (472) 472
gastroenterology & hepatology (471) 471
urology & nephrology (466) 466
expression (457) 457
infant (447) 447
graft rejection - immunology (440) 440
hematology (437) 437
drug interactions (435) 435
patients (433) 433
transplantation of organs, tissues, etc (431) 431
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10674) 10674
Japanese (184) 184
German (106) 106
French (61) 61
Chinese (41) 41
Spanish (39) 39
Portuguese (27) 27
Polish (8) 8
Korean (7) 7
Norwegian (6) 6
Italian (5) 5
Hungarian (4) 4
Russian (4) 4
Finnish (3) 3
Czech (2) 2
Danish (2) 2
Turkish (2) 2
Croatian (1) 1
Dutch (1) 1
Hebrew (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Journal of controlled release, ISSN 0168-3659, 08/2012, Volume 161, Issue 3, pp. 735 - 745
The objective of the present study was to investigate the effect of polyarginine chain length on topical delivery of surface modified NLCs. Design of... 
Nanostructured lipid carriers (NLC) | Cell penetrating peptide (CPP) | Polyarginine peptide | Skin delivery | Allergic contact dermatitis (ACD) | DRUG-DELIVERY | CHITOSAN CROSS-LINKING | TRANSDERMAL DELIVERY | MEFLOQUINE HYDROCHLORIDE MICROPARTICLES | CELL-PENETRATING PEPTIDES | TACROLIMUS OINTMENT | CHEMISTRY, MULTIDISCIPLINARY | DERMAL DELIVERY | PHARMACOLOGY & PHARMACY | H-II MESOPHASES | SUBSTANCE-P | SPANTIDE-II | Nanoparticles - chemistry | Drug Carriers - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Drug Carriers - chemistry | Peptides - administration & dosage | Ketoprofen - chemistry | Allergens - administration & dosage | Lipids - chemistry | Rats, Hairless | Skin Absorption - drug effects | Substance P - analogs & derivatives | Oligopeptides - chemistry | Cell-Penetrating Peptides - chemistry | Dermatitis, Allergic Contact - drug therapy | Peptides - chemistry | Mice, Inbred C57BL | Ketoprofen - administration & dosage | Rats | Lipids - administration & dosage | Dinitrofluorobenzene - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Mice | Nanoparticles - administration & dosage | Oligopeptides - administration & dosage | Cell-Penetrating Peptides - administration & dosage | Administration, Topical | Substance P - chemistry | Substance P - administration & dosage | Usage | Peptides | Dermatology | Analysis | Formulae, receipts, prescriptions | Dermatologic agents | Skin | Raman spectroscopy | Transdermal medication | polyarginine peptide | cell penetrating peptide (CPP) | nanostructured lipid carriers (NLC) | allergic contact dermatitis (ACD)
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 6, pp. 641 - 650
Abstract We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease... 
Hematology, Oncology and Palliative Medicine | Bone marrow transplantation | Cyclophosphamide | Histocompatibility antigens | Conditioning regimens | Lymphoma | Leukemia | TOTAL-BODY IRRADIATION | leukemia | ADULT PATIENTS | IMMUNE RECONSTITUTION | lymphoma | UNRELATED DONORS | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | bone marrow transplantation | TRANSPLANTATION | histocompatibility antigens | CORD BLOOD TRANSPLANTATION | DRUG-INDUCED TOLERANCE | cyclophosphamide | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MYCOPHENOLATE-MOFETIL | conditioning regimens | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Recombinant Proteins | Bone Marrow Transplantation - methods | Cyclophosphamide - therapeutic use | Filgrastim | Transplantation, Homologous | Bone Marrow Transplantation - immunology | Adult | Female | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Drug Administration Schedule | Graft Survival | Postoperative Complications - epidemiology | Vidarabine - analogs & derivatives | Granulocyte Colony-Stimulating Factor - therapeutic use | Postoperative Care - methods | Blood Component Transfusion | Hematologic Neoplasms - surgery | Disease-Free Survival | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Hemoglobinuria, Paroxysmal - surgery | Cyclophosphamide - pharmacology | Graft vs Host Disease - prevention & control | Aged | Vidarabine - administration & dosage | Histocompatibility | Antimitotic agents | Evaluation | Mortality | Bone marrow | Dosage and administration | Transplantation | Antineoplastic agents | T cells | Cancer | Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 60, Issue 4, pp. 872 - 884
... and in vivo expression of both CYP3A4/5 and P-gp vary substantially between individuals [1–6] . As a result, administration of a drug that is a CYP3A or P-gp substrate... 
Gastroenterology and Hepatology | Immunosuppression | Antiviral therapy | Hepatitis C | Cytochrome P450 | Calcineurin inhibitors | PHARMACOKINETIC INTERACTION | PEGYLATED INTERFERON ALPHA-2A | PROTEASE INHIBITOR BOCEPREVIR | SUSTAINED VIROLOGICAL RESPONSE | GENOTYPE 1 | HEPATITIS-C VIRUS | CAUSALITY ASSESSMENT | SIMEPREVIR TMC435 | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Hepatitis C, Chronic - metabolism | Liver Transplantation - adverse effects | Humans | Immunosuppressive Agents - pharmacokinetics | Oligopeptides - adverse effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Interactions | Anti-Bacterial Agents - adverse effects | Chemical and Drug Induced Liver Injury - etiology | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Proline - administration & dosage | Proline - analogs & derivatives | Administration, Oral | Calcineurin Inhibitors - administration & dosage | Risk Factors | Hepatitis C, Chronic - surgery | Tacrolimus - pharmacokinetics | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Chemical and Drug Induced Liver Injury - diagnosis | Antiviral Agents - adverse effects | Proline - adverse effects | Oligopeptides - administration & dosage | Anti-Bacterial Agents - administration & dosage | Complications and side effects | Liver diseases | Protease inhibitors | Proteases | Liver | Drug interactions | Organ transplant recipients | Transplantation | Hepatitis C virus | Immunosuppressive agents | Index Medicus
Journal Article
Ophthalmology (Rochester, Minn.), ISSN 0161-6420, 2017, Volume 124, Issue 3, pp. 287 - 294
Journal Article
Journal of Dermatological Science, ISSN 0923-1811, 2016, Volume 86, Issue 1, pp. 54 - 62
Highlights • TAC, not BMV, reduced scratching and improved dermatitis in Dfb-NC/Nga mice. • Strongest steroid CBP reduced scratching and improved dermatitis in... 
Dermatology | Corticosteroid | Epidermal nerve fiber | Pruritus | Tacrolimus | Atopic dermatitis | EFFICACY | INVOLVEMENT | MECHANISMS | CALCINEURIN INHIBITORS | PIMECROLIMUS | IL-31 | DERMATOLOGY | SCRATCHING BEHAVIOR | DRY-SKIN | INCREASE | Emollients - therapeutic use | Ointments - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Male | Adrenal Cortex Hormones - therapeutic use | Petrolatum - administration & dosage | Dermatitis, Atopic - etiology | Pruritus - drug therapy | Mast Cells - metabolism | Ubiquitin Thiolesterase - metabolism | Ointments - administration & dosage | Immunosuppressive Agents - administration & dosage | Disease Models, Animal | Tacrolimus - administration & dosage | Petrolatum - therapeutic use | Epidermis - metabolism | Epidermis - pathology | Emollients - administration & dosage | Cytokines - metabolism | Epidermis - drug effects | Betamethasone Valerate - administration & dosage | Treatment Outcome | Tacrolimus - therapeutic use | Animals | Dermatitis, Atopic - drug therapy | Clobetasol - administration & dosage | Betamethasone Valerate - therapeutic use | Mice | Administration, Topical | Dermatophagoides farinae - immunology | Adrenal Cortex Hormones - administration & dosage | Clobetasol - therapeutic use | Medical colleges | Corticosteroids | Health aspects | Analysis | Skin
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2018, Volume 84, Issue 7, pp. 1575 - 1586
AIMS: Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and oncological indications. We postulate... 
transplant | everolimus | cancer | nonmem | dose individualization | population pharmacokinetics | MAMMALIAN TARGET | THERAPY | PATHWAY | PHARMACOLOGY & PHARMACY | MTOR INHIBITORS | BLOOD | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Immunosuppressive Agents - pharmacokinetics | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Biological Availability | Male | Metabolic Clearance Rate | Everolimus - administration & dosage | Prednisolone - pharmacokinetics | Dose-Response Relationship, Drug | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Therapy, Combination - adverse effects | Everolimus - pharmacokinetics | Everolimus - adverse effects | Adult | Female | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Transplantation, Homologous - adverse effects | Drug Administration Schedule | Administration, Oral | Graft Rejection - prevention & control | Treatment Outcome | Tacrolimus - pharmacokinetics | Tacrolimus - adverse effects | Neoplasms - drug therapy | TOR Serine-Threonine Kinases - immunology | Drug Therapy, Combination - methods | Models, Biological | Neoplasms - immunology | Immunosuppressive Agents - adverse effects | Aged | Graft Rejection - immunology | Kidney Transplantation - adverse effects | Dosage and administration | Corticosteroids | Analysis | Prednisolone | Index Medicus | Original
Journal Article